• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为一项随机试验的一部分,响应接受前列腺癌检测邀请的男性的特征。

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.

作者信息

Walsh Eleanor I, Turner Emma L, Lane J Athene, Donovan Jenny L, Neal David E, Hamdy Freddie C, Martin Richard M

机构信息

School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, OX3 9DU, UK.

出版信息

Trials. 2016 Oct 13;17(1):497. doi: 10.1186/s13063-016-1624-6.

DOI:10.1186/s13063-016-1624-6
PMID:27737692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5064919/
Abstract

BACKGROUND

Sociodemographic characteristics are associated with participating in cancer screening and trials. We compared the characteristics of those responding with those not responding to a single invitation for prostate-specific antigen (PSA) testing for prostate cancer as part of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

METHODS

Age, rurality and deprivation among 197,763 men from 271 cluster-randomised primary care centres in the UK were compared between those responding (n = 90,300) and those not responding (n = 100,953) to a prostate cancer testing invitation.

RESULTS

There was little difference in age between responders and nonresponders. Responders were slightly more likely to come from urban rather than rural areas and were slightly less deprived than those who did not respond.

CONCLUSION

These data indicate similarities in age and only minor differences in deprivation and urban location between responders and nonresponders. These differences were smaller, but in the same direction as those observed in other screening trials.

TRIAL REGISTRATION

ISRCTN92187251 . Registered on 29 November 2004.

摘要

背景

社会人口统计学特征与参与癌症筛查及试验相关。作为前列腺癌前列腺特异性抗原(PSA)检测整群随机试验(CAP)的一部分,我们比较了对前列腺癌PSA检测单次邀请做出回应者与未回应者的特征。

方法

在英国271个整群随机初级保健中心的197,763名男性中,比较了对前列腺癌检测邀请做出回应者(n = 90,300)和未回应者(n = 100,953)的年龄、居住在农村还是城市以及贫困程度。

结果

回应者与未回应者的年龄差异不大。回应者来自城市地区而非农村地区的可能性略高,且贫困程度略低于未回应者。

结论

这些数据表明,回应者与未回应者在年龄上相似,在贫困程度和城市居住地点上仅有微小差异。这些差异较小,但与其他筛查试验中观察到的差异方向相同。

试验注册

ISRCTN92187251。于2004年11月29日注册。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad16/5064919/839881660959/13063_2016_1624_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad16/5064919/44b833911103/13063_2016_1624_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad16/5064919/839881660959/13063_2016_1624_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad16/5064919/44b833911103/13063_2016_1624_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad16/5064919/839881660959/13063_2016_1624_Fig2_HTML.jpg

相似文献

1
Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.作为一项随机试验的一部分,响应接受前列腺癌检测邀请的男性的特征。
Trials. 2016 Oct 13;17(1):497. doi: 10.1186/s13063-016-1624-6.
2
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.基于低强度前列腺特异性抗原的筛查干预对前列腺癌死亡率的影响:CAP随机临床试验
JAMA. 2018 Mar 6;319(9):883-895. doi: 10.1001/jama.2018.0154.
3
Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).《前列腺癌 PSA 检测的集群随机试验(CAP)设计和初步招募结果》。
Br J Cancer. 2014 Jun 10;110(12):2829-36. doi: 10.1038/bjc.2014.242. Epub 2014 May 27.
4
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.前列腺特异性抗原筛查与 15 年前列腺癌死亡率:CAP 随机临床试验的二次分析。
JAMA. 2024 May 7;331(17):1460-1470. doi: 10.1001/jama.2024.4011.
5
Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.英国评估前列腺癌筛查和治疗的试验的最新结果:CAP 和 ProtecT 研究。
Eur J Cancer. 2010 Nov;46(17):3095-101. doi: 10.1016/j.ejca.2010.09.016.
6
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.前列腺癌筛查用 PSA、激肽释放酶组和 MRI:ProScreen 随机试验。
JAMA. 2024 May 7;331(17):1452-1459. doi: 10.1001/jama.2024.3841.
7
Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.机会性检测与有组织的前列腺特异性抗原筛查:哥德堡随机人群前列腺癌筛查试验 18 年后的结果。
Eur Urol. 2015 Sep;68(3):354-60. doi: 10.1016/j.eururo.2014.12.006. Epub 2014 Dec 31.
8
The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.评估前列腺癌遗传风险对初级保健中 PSA 检测应用的影响:一项聚类随机对照试验。
PLoS Med. 2020 Feb 7;17(2):e1003033. doi: 10.1371/journal.pmed.1003033. eCollection 2020 Feb.
9
Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).在癌症筛查试验中提交给终点委员会用于死因判定的信息标准化——从CAP(前列腺癌PSA检测的整群随机试验)中吸取的经验教训
BMC Med Res Methodol. 2015 Jan 23;15:6. doi: 10.1186/1471-2288-15-6.
10
Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.使用前列腺特异性抗原和一组激肽释放酶标志物提高致命性前列腺癌筛查的特异性:一项巢式病例对照研究。
Eur Urol. 2015 Aug;68(2):207-13. doi: 10.1016/j.eururo.2015.01.009. Epub 2015 Feb 11.

引用本文的文献

1
Associations between neighbourhood characteristics and participation in a population-based organised prostate cancer testing (OPT) programme: A register-based study of 50-year-old men.社区特征与参与基于人群的有组织前列腺癌检测(OPT)项目之间的关联:一项针对50岁男性的基于登记册的研究。
PLoS One. 2025 Apr 29;20(4):e0322643. doi: 10.1371/journal.pone.0322643. eCollection 2025.
2
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.主动监测、根治性前列腺切除术和根治性放疗在 PSA 检测到的局限性前列腺癌中的应用:ProtecT 三臂 RCT。
Health Technol Assess. 2020 Aug;24(37):1-176. doi: 10.3310/hta24370.
3

本文引用的文献

1
Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.转移性前列腺癌发病率与前列腺特异性抗原检测:来自欧洲前列腺癌筛查随机研究的新见解
Eur Urol. 2015 Nov;68(5):885-90. doi: 10.1016/j.eururo.2015.02.042. Epub 2015 Mar 16.
2
The Finnish prostate cancer screening trial: analyses on the screening failures.芬兰前列腺癌筛查试验:筛查失败情况分析
Int J Cancer. 2015 May 15;136(10):2437-43. doi: 10.1002/ijc.29300. Epub 2014 Nov 10.
3
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
基于低强度前列腺特异性抗原的筛查干预对前列腺癌死亡率的影响:CAP随机临床试验
JAMA. 2018 Mar 6;319(9):883-895. doi: 10.1001/jama.2018.0154.
4
A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial.前瞻性队列和扩展综合队列设计为了解一项实用试验(即 ProtecT 前列腺癌试验)的普遍性提供了一些见解。
J Clin Epidemiol. 2018 Apr;96:35-46. doi: 10.1016/j.jclinepi.2017.12.019. Epub 2017 Dec 27.
局部前列腺癌的主动监测、根治性前列腺切除术或放疗:ProtecT 随机 3 期试验的研究设计及诊断和基线结果。
Lancet Oncol. 2014 Sep;15(10):1109-18. doi: 10.1016/S1470-2045(14)70361-4. Epub 2014 Aug 19.
4
Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).《前列腺癌 PSA 检测的集群随机试验(CAP)设计和初步招募结果》。
Br J Cancer. 2014 Jun 10;110(12):2829-36. doi: 10.1038/bjc.2014.242. Epub 2014 May 27.
5
European transnational ecological deprivation index and participation in population-based breast cancer screening programmes in France.欧洲跨国生态剥夺指数与法国基于人群的乳腺癌筛查项目参与情况
Prev Med. 2014 Jun;63:103-8. doi: 10.1016/j.ypmed.2013.12.007. Epub 2013 Dec 15.
6
Socioeconomic variation and prostate specific antigen testing in the community: a United Kingdom based population study.社区中前列腺特异性抗原检测的社会经济差异:基于英国的人群研究。
J Urol. 2013 Oct;190(4):1207-12. doi: 10.1016/j.juro.2013.04.044. Epub 2013 Apr 19.
7
The importance of socioeconomic factors for compliance and outcome at screening for abdominal aortic aneurysm in 65-year-old men.65 岁男性筛查腹主动脉瘤时社会经济因素对依从性和结果的重要性。
J Vasc Surg. 2013 Jul;58(1):50-5. doi: 10.1016/j.jvs.2012.12.080. Epub 2013 Mar 29.
8
Excess all-cause mortality in the evaluation of a screening trial to account for selective participation.评估筛选试验时,过度的全因死亡率需要考虑选择性参与。
J Med Screen. 2013 Mar;20(1):39-45. doi: 10.1177/0969141312474443. Epub 2013 May 13.
9
Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).前列腺癌筛查可降低发生转移性疾病的风险:来自前列腺癌筛查欧洲随机研究(ERSPC)的结果。
Eur Urol. 2012 Nov;62(5):745-52. doi: 10.1016/j.eururo.2012.05.068. Epub 2012 Jun 7.
10
Nonparticipation in a population-based trial to increase colorectal cancer screening.不参与基于人群的提高结直肠癌筛查的试验。
Am J Prev Med. 2012 Apr;42(4):390-7. doi: 10.1016/j.amepre.2011.11.014.